Proactive Investors - Run By Investors For Investors unit abandons plan to sell pharmaceutical products, CNBC says

Amazon found it difficult to persuade hospitals to change the way they purchase products box
Amazon Business failed to convince hospitals to change the way they purchase products Inc.'s (NASDAQ:AMZN) Business unit, which sells bulk items to companies, has abandoned a plan to sell pharmaceutical products after weighing it last year, according to a report by CNBC, citing people familiar with the matter.

Amazon Business’s decision is partly because it failed to persuade hospitals to change the way they purchase products and cut out middlemen from the deals, CNBC said.

Another issue was that Amazon Business would have had to build an extensive logistics network that could accomodate drugs and other pharmaceutical products, which are sensitive to temperature, according to the report.

The retreat from the pharmaceutical space was seen as favorable by investors in pharmacies. CVS Health Corp. gained 5.7% to US$67.00 in early afternoon trading, while the Walgreens Boots Alliance Inc., which owns Walgreens and Boots, jumped 4.1% to US$66.43.

Amazon Business may consider getting into pharmaceuticals again as it gains size, according to CNBC.

Shares of were up 0.64% at US$1,439.50.

View full AMZN profile View Profile Timeline

Related Articles

Scans and MRI
November 28 2018
The firm's subsidiary, Imaging Biometrics, recently appointed a South Korean distributor a few weeks after receiving the first commercial order for its StoneChecker technology
December 03 2018
“I think customers are seeing that we do offer value and that really is the answer,” said chief executive John Nichols

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use